Li Lin1, Bao-Ping Zhu2, Liang Cai3. 1. Department of Emergency Medicine, Wuhan No.1 Hospital, Wuhan, China. 2. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: tbxbrz@163.com. 3. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Abstract
OBJECTIVES: The present study was aimed to establish a model of chronic prostatitis in rat with the use of intraprostatic injection of Complete Freund's Adjuvant, and to examine the anti-inflammatory and analgesic effects of melittin on the newly-developed chronic prostatic pain model. METHODS: Adult male Sprague-Dawley rats were injected with Complete Freund's Adjuvant (CFA) into the prostate. Twelve days after model rats of the treatment group were injected melittin into the prostate, while those of the control group received sterile saline injection. The nociceptive effects of CFA were evaluated by using a behavior approach (i.e. mechanical pain threshold measurement) on the day of CFA injection and 6, 12, and 18days after CFA injection. After the in-live study was done, the prostate was collected for histological examination of inflammatory cell infiltration. Levels of cyclooxygenase (COX)-2 in prostate and glial fibrillary acidic protein (GFAP) in spinal cord were determined using immunohistochemistry. Rats of the sham control group received intraprostatic injection of sterile saline and were studied using the same methods RESULTS: Intraprostatic CFA injection induced local allodynia that lasted over at least 2 weeks. The pain behavior of rat was associated with increases in inflammatory cell infiltration into the prostate. Levels of COX-2 in prostate and GFAP in spinal cord were also elevated. Treatment with melittin significantly raised pain threshold, decreased inflammatory infiltrates, and suppressed COX-2 and GFAP expression. CONCLUSION: Intraprostatic injection of CFA induced neurogenic prostatitis and prostatic pain. The established model will be useful to the study of CP/CPPS pathogenesis. Melittin demonstrated profound anti-inflammatory and analgesic effects on the chronic prostatic pain model, suggesting melittin may hold promise as a novel therapeutic for treatment of CP/CPPS.
OBJECTIVES: The present study was aimed to establish a model of chronic prostatitis in rat with the use of intraprostatic injection of Complete Freund's Adjuvant, and to examine the anti-inflammatory and analgesic effects of melittin on the newly-developed chronic prostatic pain model. METHODS: Adult male Sprague-Dawley rats were injected with Complete Freund's Adjuvant (CFA) into the prostate. Twelve days after model rats of the treatment group were injected melittin into the prostate, while those of the control group received sterile saline injection. The nociceptive effects of CFA were evaluated by using a behavior approach (i.e. mechanical pain threshold measurement) on the day of CFA injection and 6, 12, and 18days after CFA injection. After the in-live study was done, the prostate was collected for histological examination of inflammatory cell infiltration. Levels of cyclooxygenase (COX)-2 in prostate and glial fibrillary acidic protein (GFAP) in spinal cord were determined using immunohistochemistry. Rats of the sham control group received intraprostatic injection of sterile saline and were studied using the same methods RESULTS: Intraprostatic CFA injection induced local allodynia that lasted over at least 2 weeks. The pain behavior of rat was associated with increases in inflammatory cell infiltration into the prostate. Levels of COX-2 in prostate and GFAP in spinal cord were also elevated. Treatment with melittin significantly raised pain threshold, decreased inflammatory infiltrates, and suppressed COX-2 and GFAP expression. CONCLUSION: Intraprostatic injection of CFA induced neurogenic prostatitis and prostatic pain. The established model will be useful to the study of CP/CPPS pathogenesis. Melittin demonstrated profound anti-inflammatory and analgesic effects on the chronic prostatic pain model, suggesting melittin may hold promise as a novel therapeutic for treatment of CP/CPPS.
Authors: Shantanu Guha; Ryan P Ferrie; Jenisha Ghimire; Cristina R Ventura; Eric Wu; Leisheng Sun; Sarah Y Kim; Gregory R Wiedman; Kalina Hristova; Wimley C Wimley Journal: Biochem Pharmacol Date: 2021-09-17 Impact factor: 6.100
Authors: Brenda Fernanda Moreira Castro; Carolina Nunes da Silva; Lídia Pereira Barbosa Cordeiro; Sarah Pereira de Freitas Cenachi; Daniel Vitor Vasconcelos-Santos; Renes Resende Machado; Luiz Guilherme Dias Heneine; Luciana Maria Silva; Armando Silva-Cunha; Silvia Ligório Fialho Journal: Curr Res Pharmacol Drug Discov Date: 2022-05-11
Authors: Jiho Choi; Changhoon Jeon; Ji Hwan Lee; Jo Ung Jang; Fu Shi Quan; Kyungjin Lee; Woojin Kim; Sun Kwang Kim Journal: Toxins (Basel) Date: 2017-10-31 Impact factor: 4.546